VANDA Pharmaceuticals recently announces FDA grants Orphan Drug Designation for VGT-1849B, a novel and selective candidate for the treatment of Polycythemia Vera
WASHINGTON — PRNewswire — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) on Aug. 28, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera (PV).
